---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106918"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:28:47.738018+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CalciMedica Q2 net loss $6.0M ($0.40/sh); cash $18.0M; KOURAGE trial data expected early 2026

## Summary
- Net loss of $6.0M, or $0.40 per share, vs $4.0M ($0.36) in Q2 2024.
- Cash and investments $18.0M; expected to fund operations into mid-2026.
- R&D expenses $4.1M, G&A $2.6M; other income fell to $0.7M from $2.6M.
- Enrollment ongoing in Phase 2 KOURAGE trial for AKI with respiratory failure; 150 patients planned.
- Initial FDA meeting on Auxora for acute pancreatitis constructive; pivotal trial alignment expected end-2025.

## SEC filing metadata
- accession: 0000950170-25-106918
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000095017025106918/0000950170-25-106918-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000095017025106918/ck0001534133-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106918
- JSON: https://secwatch.observer/filing/0000950170-25-106918.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106918.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.